Polaryx Therapeutics names Will Charlton chief medical officer
Polaryx Therapeutics appointed Will Charlton, M.D., M.A.S. as chief medical officer to lead clinical execution for PLX-200 and the SOTERIA Phase 2 trial.
Polaryx Therapeutics appointed Will Charlton, M.D., M.A.S. as Chief Medical Officer to lead clinical execution for PLX-200 and the SOTERIA Phase 2 trial.Key Highlights:Original SEC Filing: Polaryx Therapeutics, Inc. [ PLYX ] - 8-K - Sep.
01, 2026This is an AI-powered summary.
It may contain inaccur…